| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
D-Asparagine targets the N-methyl-D-aspartate (NMDA) receptor, acting as an agonist. It is also used by bacteria (such as Saccharomyces cerevisiae) as a sole nitrogen source for replication. It is a substrate for the external yeast asparaginase but is a poor substrate for the internal enzyme.
|
|---|---|
| ln Vitro |
D-Asparagine has been found to have various biological activities, including neurotransmitter activity, hormone regulation, and immune system modulation. It acts as an agonist for the NMDA receptor, which is involved in learning and memory. Its activity is studied in the context of protein structure and enzyme specificity.
|
| ln Vivo |
In vivo, D-Asparagine is used by bacteria as a nitrogen source. In mammals, D-amino acids, including D-asparagine, are present in trace amounts and may have physiological roles. Its effects on NMDA receptors suggest potential involvement in neurotransmission. However, specific in vivo pharmacological effects in mammals are not extensively characterized.
|
| Enzyme Assay |
In vitro enzyme assays with D-Asparagine typically involve studying asparaginase activity. The compound is used as a substrate to measure enzyme activity, particularly to distinguish between external and internal yeast asparaginases. Standard assays involve incubating D-asparagine with enzyme preparations and measuring the release of ammonia or aspartate by spectrophotometric or chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with D-Asparagine involve treating cells to study its effects on NMDA receptor signaling. Neuronal cell lines expressing NMDA receptors are treated with D-asparagine, and endpoints include assessment of calcium influx, neuronal activity, and cell viability. These experiments characterize the compound's neuroactive properties and receptor interactions.
|
| Animal Protocol |
In vivo animal experiments with D-Asparagine are not commonly performed as the compound is a research chemical rather than a therapeutic agent. If used, it would be to study the effects of D-amino acids on NMDA receptor function or to investigate bacterial metabolism. Its primary significance is in research as a tool for studying enzyme specificity and protein structure.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of D-Asparagine are not well characterized. As a small, polar amino acid, it is expected to be absorbed and distributed throughout the body. It may be metabolized by D-amino acid oxidase or other enzymes. Specific PK data are not available in the literature.
|
| Toxicity/Toxicokinetics |
D-Asparagine is classified with hazard code Xn (Harmful), with risk statements indicating it is harmful if swallowed, inhaled, or in contact with skin, and irritating to eyes, respiratory system, and skin. Appropriate safety precautions, including protective clothing and eye protection, should be taken when handling.
|
| References | |
| Additional Infomation |
D-Asparagine is the optically active form of asparagine with the D-configuration. It is a D-α-amino acid and also an asparagine. It is the conjugate base of D-asparagine salts. It is the conjugate acid of D-asparagine acids. It is the enantiomer of L-asparagine. It is the tautomer of the D-asparagine zwitterion. It is a non-essential amino acid involved in the metabolic regulation of nerve and brain tissue cell function. It is biosynthesized from aspartic acid and ammonia by asparagine synthase. (Excerpt from A Concise Encyclopedia of Biochemistry and Molecular Biology, 3rd Edition) D-Asparagine has been reported in Arabidopsis thaliana and Saccharomyces cerevisiae, with relevant data available. See also: Asparagine (note moved to).
D-Asparagine is a D-enantiomer of asparagine used in peptide synthesis and protein engineering research. It acts as an agonist for the NMDA receptor and is involved in studies of neurotransmitter activity, hormone regulation, and immune system modulation. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C4H8N2O3
|
|---|---|
| Molecular Weight |
132.12
|
| Exact Mass |
132.053
|
| CAS # |
2058-58-4
|
| PubChem CID |
439600
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
438.0±40.0 °C at 760 mmHg
|
| Melting Point |
234 - 235 °C
|
| Flash Point |
218.7±27.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.533
|
| LogP |
-1.51
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
134
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@H](C(=O)O)N)C(=O)N
|
| InChi Key |
DCXYFEDJOCDNAF-UWTATZPHSA-N
|
| InChi Code |
InChI=1S/C4H8N2O3/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H2,6,7)(H,8,9)/t2-/m1/s1
|
| Chemical Name |
(2R)-2,4-diamino-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 33.33 mg/mL (252.27 mM)
DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5689 mL | 37.8444 mL | 75.6888 mL | |
| 5 mM | 1.5138 mL | 7.5689 mL | 15.1378 mL | |
| 10 mM | 0.7569 mL | 3.7844 mL | 7.5689 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
